FDA accepts CVTX's Ranexa NDA

The FDA accepted for filing an NDA from CV Therapeutics (CVTX) for Ranexa ranolazine to treat chronic angina. Ranexa partially inhibits fatty acid oxidation (pFOX). In CVTX's Phase III CARISA trial th...